Detailed Information on Publication Record

ANKER, S.D., J. BUTLER, G. FILIPPATOS, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE-VALENZUELA, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, D. SIM, Jindřich ŠPINAR, I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, P. CARSON, C. S. P. LAM, N. MARX, C. ZELLER, N. SATTAR, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. Waltham: Massachussetts Medical Society, 2021, vol. 385, No 16, p. 1451-1461. ISSN 0028-4793. Available from: https://dx.doi.org/10.1056/NEJMoa2107038.

Other formats: BibTeX LaTeX RIS

TY  - JOUR
ID  - 1790339
AU  - Anker, S.D. - Butler, J. - Filippatos, G. - Ferreira, J. P. - Bocchi, E. - Bohm, M. - Brunner-La, Rocca H. P. - Choi, D. J. - Chopra, V. - Chuquiure-Valenzuela, E. - Giannetti, N. - Gomez-Mesa, J. E. - Janssens, S. - Januzzi, J. L. - Gonzalez-Juanatey, J. R. - Merkely, B. - Nicholls, S. J. - Perrone, S. V. - Pina, I. L. - Ponikowski, P. - Senni, M. - Sim, D. - Špinar, Jindřich - Squire, I. - Taddei, S. - Tsutsui, H. - Verma, S. - Vinereanu, D. - Zhang, J. - Carson, P. - Lam, C. S. P. - Marx, N. - Zeller, C. - Sattar, N. - Jamal, W. - Schnaidt, S. - Schnee, J. M. - Brueckmann, M. - Pocock, S. J. - Zannad, F. - Packer, M.
PY  - 2021
TI  - Empagliflozin in Heart Failure with a Preserved Ejection Fraction
JF  - New England Journal of Medicine
VL  - 385
IS  - 16
SP  - 1451-1461
EP  - 1451-1461
PB  - Massachussetts Medical Society
SN  - 00284793
KW  - Heart Failure
KW  - Empagliflozin
KW  - Preserved Ejection Fraction
UR  - https://www.nejm.org/doi/10.1056/NEJMoa2107038
N2  - BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
ER  -

Basic information
Original name	Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Authors	ANKER, S.D. (guarantor), J. BUTLER, G. FILIPPATOS, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE-VALENZUELA, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, D. SIM, Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, P. CARSON, C. S. P. LAM, N. MARX, C. ZELLER, N. SATTAR, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER.
Edition	New England Journal of Medicine, Waltham, Massachussetts Medical Society, 2021, 0028-4793.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30218 General and internal medicine
Country of publisher	Slovenia
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 176.079
RIV identification code	RIV/00216224:14110/21:00122279
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.1056/NEJMoa2107038
UT WoS	000691622000001
Keywords in English	Heart Failure; Empagliflozin; Preserved Ejection Fraction
Tags	14110115, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/12/2021 10:49.

Abstract
BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

Abstract

BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.